Life sciences R&D credits 2026 are among the most valuable tax incentives available. Drug development, clinical trials, medical device design, and biotech research all generate significant qualified research expenses.
However, a February 2026 ruling in George v. Commissioner serves as a cautionary tale. The U.S. Tax Court confirmed that agricultural research can qualify, but simultaneously denied a substantial portion of the taxpayer’s credits due to a lack of contemporaneous documentation. The case reinforces that documentation is non-negotiable, not a green light for expansive claims.
Understanding life sciences R&D credits 2026 starts with the federal four-part test and the OBBBA’s immediate expensing provision.
Federal Foundation
IRC Section 41 Four-Part Test
Qualifying research must meet all four IRS requirements under IRC Section 41: permitted purpose, elimination of uncertainty, process of experimentation, and technological in nature. This is the base layer every state program builds on.
The four-part test must be applied separately to each business component. A business component is any product, process, computer software, technique, formula, or invention held for sale, lease, license, or used in a trade or business.
Section 174A Immediate Expensing
The One Big Beautiful Bill Act (OBBBA), signed in July 2025, restored full, immediate expensing of domestic R&D costs for tax years beginning after December 31, 2024. This reverses the five-year amortization requirement that took effect in 2022.
Foreign R&D must still be capitalized and amortized over 15 years.
Form 6765 Section G Reporting
Section G requires reporting business component detail on Form 6765. It is optional for tax year 2025 and becomes mandatory starting tax year 2026 for most filers.
Exceptions: Qualified Small Businesses electing the payroll tax offset and taxpayers with total QREs of 1.5 million or less and gross receipts of 50 million or less are exempt from mandatory Section G reporting.
Payroll Tax Offset
Pre-revenue Qualified Small Businesses can apply up to 500 thousand of the federal R&D credit against payroll (FICA and Medicare) tax liability. This is a critical lever for clinical-stage biotechs with no income tax liability yet.
Retroactive Small-Business Election
Businesses under the 31 million average gross receipts threshold could amend 2022-2024 returns to apply Section 174A retroactively. That window closed on July 6, 2026.
State Programs for Life Sciences R&D Credits 2026
State R&D credit rules do not mirror federal rules. Clinical trial expenses, geographic requirements, and documentation standards all vary. A claim built only around federal QREs typically leaves state-level money unclaimed.
Beyond federal, life sciences R&D credits 2026 include powerful state-level programs that can add significant cash flow.
Here are the most valuable state programs for life sciences companies operating in these markets.
New York: Life Sciences Research and Development Tax Credit
New York offers a fully refundable credit for qualified life sciences companies. The credit is equal to 15% of R&D expenditures for companies with 10 or more employees, or 20% for companies with fewer than 10 employees.
Key details:
-
Annual per-entity cap: 500 thousand
-
Lifetime cap: 1.5 million (up to three consecutive years)
-
Refundability: 100% fully refundable
-
Statewide allocation: 10 million annually
Who qualifies: A “new business” certified by Empire State Development as a qualified life sciences company. The new business requirement means the company must not be more than 50% owned by another NY taxpayer, must not have been a NY taxpayer for more than five years, and must not be “substantially similar” to an existing NY taxpayer.
Eligible scientific domains: Agricultural biotechnology, biopharmaceuticals, bioinformatics, biomedical engineering, genomics, medical devices, medical nanotechnology, and related fields.
Application process: Two-step process. First, complete a Consolidated Funding Application or Life Sciences Tax Credit Application with ESD. Upon approval, ESD issues a Certificate of Tax Credit. Then, attach the certificate to Form IT-648 (or CT-648 for corporations) with the annual tax return.
New York City Biotech Tax Credit: NYC offers an additional refundable credit of up to 250 thousand per year for Qualified Emerging Technology Companies from a 3 million citywide pool.
New Hampshire: Life Sciences R&D Tax Credit
New Hampshire’s life sciences R&D credit received a significant boost effective January 1, 2026. The aggregate value of all R&D credits that can be claimed increased from 7 million to 10 million. The maximum credit per entity doubled from 50 thousand to 100 thousand.
Key limitation: The New Hampshire credit is limited to qualified manufacturing wages only—not supplies, contract research, or other expenses. The credit requires wages paid to employees for services rendered in New Hampshire and treated as qualified research expenses under Section 41(b).
Filing deadline: Form DP-165 must be filed by June 30 following the close of the tax year.
Why it matters: New Hampshire’s life sciences industry includes more than 600 companies across medical device manufacturing, R&D, pharmaceutical manufacturing, and medical diagnostics. The industry supports 11,000 jobs with average salaries of nearly 130 thousand, making it the highest-paying industry in the state.
Massachusetts: MLSC Life Sciences Tax Incentive Program
Massachusetts offers competitive awards of refundable credits through the Massachusetts Life Sciences Center (MLSC). The program includes investment tax credits, jobs credits, and user fee exemptions drawn from an annual pool.
2026 application window: January 12 to March 31.
Best for: Companies with Massachusetts-based R&D or manufacturing headcount, including pre-revenue biotechs.
The credit is refundable for up to 90% of the balance exceeding the excise due.
New Jersey: Technology Business Tax Certificate Transfer (NOL) Program
New Jersey allows unprofitable tech and biotech companies (under 225 employees) to sell unused net operating losses and R&D credits to a profitable New Jersey taxpayer.
Key details:
-
Minimum sale price: 80% of face value
-
Annual statewide cap: 75 million
-
Lifetime cap per company: 20 million
Best for: Pre-revenue biotechs that need immediate cash rather than a future-year offset.
Connecticut: Proposed Expansion for Pass-Through Entities (Pending)
Connecticut has proposed expanding its R&D tax credit to pass-through entities (LLCs, S-corps, partnerships) through a new voucher program. As of August 2026, two parallel bills (including H.B. 5059) are moving through the state legislature but have not yet been enacted into law.
Proposed details:
-
Credit rate: 6% of qualifying R&D expenditures
-
Annual per-company cap: 1 million
-
Statewide program cap: 25 million annually
-
Refundability: Companies with little or no tax liability could receive a portion of unused credits as a refund
-
Biotech carryback: Qualifying biotech companies could receive refunds of up to 90% of their credit value
Who would qualify: Businesses with under 70 million in gross annual income organized as pass-through entities, including early-stage biotech, manufacturers, technology startups, and R&D-intensive professional services firms.
Status: Proposed legislation only. Not yet law.
California: R&D Credit (SB 711, Effective 2025)
California’s R&D credit was updated under SB 711, effective 2025. It now uses an Alternative Simplified Credit method. The credit rate is 3% of qualifying California QREs (or 1.3% for those without prior-year QREs).
Key details:
-
Refundability: Nonrefundable
-
Carryforward: Indefinite
-
Temporary cap: Subject to a 5 million annual combined-credit cap (2024-2026) with an FTB 3870 refund election for the excess
Best for: California-based labs and R&D teams with meaningful California tax liability or a multi-year runway to use carryforwards.
How to Stack Federal and State Claims
-
Map every location where qualifying activity happens: headquarters, wet labs, contract research organizations, and remote R&D staff. Credits often follow where the work is performed, not just where the company is incorporated.
-
Build one documentation system that satisfies the strictest jurisdiction you are claiming in, then layer state-specific forms on top rather than maintaining separate records per state.
-
Sequence applications around deadlines. Several of these programs (MLSC, NJ NOL sale, NYC Biotech Credit) run on competitive, capped, or application-based cycles that do not align with your tax return due date.
-
For pre-revenue companies, prioritize refundable or sellable credits (NJ NOL sale, MLSC refundable ITC, federal payroll offset) over nonrefundable credits that only offset a tax liability you do not have yet.
Documentation Best Practices
The George v. Commissioner ruling reinforced that contemporaneous records are non-negotiable. Reconstructed studies assembled years later do not hold up in court.
What to track:
-
Clinical trial protocols and results
-
Lab notebooks and experiment records
-
Time allocation by employee and project
-
Vendor invoices and contract research agreements
-
Evidence of technical uncertainty at project outset
How to track it:
-
Use project codes for R&D time
-
Maintain dated lab records and test results
-
Keep all documentation organized and accessible
Bottom Line
Life sciences R&D credits 2026 are more valuable than ever. The OBBBA restored immediate federal expensing, Form 6765 Section G reporting is taking effect, and states like New York, New Hampshire, Massachusetts, New Jersey, and California offer significant incentives.
For pre-revenue biotechs, refundable credits provide immediate cash flow rather than future-year offsets. Stacking federal and state programs can meaningfully extend runway without giving up equity.
Call (844) 463-2400 or email hello@indagotax.com to discuss which programs your life sciences company qualifies for.